A incidência de trombocitemia essencial (TE) nos EUA é de 1.55 por 100,000 pessoas-ano (dados de 2002 a 2016).[12]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
Na Europa, a incidência varia entre 0.38 e 1.7 por 100,000 pessoas por ano.[13]Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014 Apr;92(4):289-97.
http://www.ncbi.nlm.nih.gov/pubmed/24372927?tool=bestpractice.com
No Reino Unido, a incidência anual de TE é de 4.2 por 100,000, com uma estimativa de 2,720 pessoas recém-diagnosticadas a cada ano (dados de 2010 a 2019).[14]The Haematological Malignancy Research Network. Factsheets: essential thrombocythaemia 2022. Apr 2024 [internet publication].
https://hmrn.org/factsheets
A TE ocorre mais comumente em mulheres (razão entre mulheres/homens de aproximadamente 0.8).[12]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
[14]The Haematological Malignancy Research Network. Factsheets: essential thrombocythaemia 2022. Apr 2024 [internet publication].
https://hmrn.org/factsheets
A incidência é maior entre os negros nos EUA.[12]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
A TE afeta mais comumente pessoas idosas (aproximadamente 66% dos pacientes nos EUA têm idade ≥60 anos no momento do diagnóstico), mas pessoas mais jovens podem desenvolver a doença.[12]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
A idade mediana no momento do diagnóstico é de 67 anos nos EUA e 72 anos no Reino Unido.[12]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
[14]The Haematological Malignancy Research Network. Factsheets: essential thrombocythaemia 2022. Apr 2024 [internet publication].
https://hmrn.org/factsheets
A prevalência na população geral é de aproximadamente 30 a 60 por 100,000.[15]Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006 Apr;32(3):171-3.
http://www.ncbi.nlm.nih.gov/pubmed/16673273?tool=bestpractice.com
[16]Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014 Mar;55(3):595-600.
http://www.ncbi.nlm.nih.gov/pubmed/23768070?tool=bestpractice.com
[17]Ma X, Vanasse G, Cartmel B, et al. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008 May;83(5):359-62.
https://www.doi.org/10.1002/ajh.21129
http://www.ncbi.nlm.nih.gov/pubmed/18181200?tool=bestpractice.com
[18]Brière JB. Essential thrombocythemia. Orphanet J Rare Dis. 2007 Jan 8;2:3.
https://www.doi.org/10.1186/1750-1172-2-3
http://www.ncbi.nlm.nih.gov/pubmed/17210076?tool=bestpractice.com